PDCD1 and classic Hodgkin lymphoma: Patients with relapsed/refractory cHL who had high pretreatment peripheral platelet‐to‐neutrophil ratio acquired increased complete response rate and longer progression‐free survival after anti‐PD‐1‐based therapy.